TMB-365 and TMB-380 Keep HIV Suppressed in Study

TaiMed Biologics reports Phase 2a results for a long-acting antibody maintenance regimen published in The Lancet HIV.

Updated on Nov. 10, 2026 in Biotech

Flat-color editorial illustration of a clear intravenous bag hanging beside an empty padded chair, evoking a long-acting HIV treatment infusion.
TaiMed Biologics reported Phase 2a results showing 94% of participants stayed virologically suppressed on TMB-365 and TMB-380 given every eight weeks, published in The Lancet HIV. AI Illustration. Upload story photo >

TaiMed Biologics published Phase 1b/2a results of TMB-365 combined with TMB-380 in The Lancet HIV, with the same findings presented at HIV Glasgow 2026. In the per-protocol analysis, 16 of 17 participants (94%) remained below 50 copies/mL of HIV-1 RNA at Week 24.

Why it matters

The regimen was tested as a long-acting alternative to daily oral antiretroviral therapy, which could reduce the burden of daily dosing for people living with HIV. Bodyweight-based dosing was added to the next study phase after body weight was identified as a covariate of TMB-365 exposure.

The Phase 2a study enrolled 20 intention-to-treat participants, with 16 (80%) suppressed at Week 24 after receiving 4,800 mg each of TMB-365 and TMB-380 intravenously every eight weeks. Results come from a small study without pretreatment susceptibility screening, and the regimen's longer-term durability remains to be tested in larger populations.

The players

TaiMed Biologics

TaiMed Biologics is a Taipei, Taiwan-based biotechnology company developing antibody-based therapies for HIV.

The details

Participants who were virologically suppressed on oral antiretroviral therapy discontinued oral treatment and received intravenous infusions of TMB-365 and TMB-380 every eight weeks for 24 weeks. No participant met the protocol-defined criteria for confirmed virologic failure, and treatment-emergent adverse events were mild or moderate with no serious events, deaths, or opportunistic infections reported.

Timeline

  1. Week 24: Participants' HIV-1 RNA suppression was measured at the end of the Phase 2a study.

  2. HIV Glasgow 2026: The findings were presented in an oral session in Glasgow, Scotland.

  3. November 10, 2026: The study was published in The Lancet HIV.

Big Picture

Long-acting injectable HIV regimens such as cabotegravir-based treatments have shifted maintenance therapy toward less frequent dosing. TMB-365 and TMB-380 pursue the same goal through broadly neutralizing antibodies, with infusions every eight weeks rather than daily pills.

If approved, a regimen given every eight weeks could reduce the need for daily oral pills for people with suppressed HIV. The study has not yet established whether these results hold in larger or more diverse populations.

The takeaway

Long-acting HIV maintenance is advancing beyond small-molecule injectables, but the TMB-365 and TMB-380 data remain preliminary and await the larger Phase 2b study.

What happens next

The ongoing Phase 2b study is designed to provide a more rigorous assessment of the regimen's potential as long-acting maintenance therapy in a larger population.

Further reading

Explore more biotech developments shaping treatment research worldwide.